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Background. Model for End-Stage Liver Disease (MELD) score is used to assess the
severity of chronic liver disease. It is implemented in transplantology in the process of
qualification for urgent liver transplant. The aim of our study was to assess the liver
function of patients qualified for lung transplant using MELD score, taking under
consideration mean pulmonary artery pressure as an important risk factor of death.
Methods. The study group consisted of 123 patients qualified for lung transplant in
Silesian Center for Heart Diseases between 2004 and 2017. Data relevant for MELD score
calculations and medial pulmonary artery pressure were acquired from medical records.
Results. The average MELD score among patients qualified for lung transplant was 8.24
points, and mean pulmonary pressure (mPAP) was 35.02 mm Hg. Patients with idiopathic
pulmonary artery hypertension acquired the highest MELD and highest mPAP results (13.1
points and 57.7 mm Hg, respectively). Patients with idiopathic pulmonary fibrosis presented
higher meanMELD-Na score among those with pulmonary arterial hypertension than those
without pulmonary arterial hypertension (36.59mmHg; 7.74 points vs 18mmHg; 6.5 points).
There is strong positive correlation between MELD-Na and mPAP among patients who
underwent lung transplant because of idiopathic pulmonary fibrosis.
Conclusions. This is the first study in the worldwide literature assessing MELD-Na as a
predictor of survival among patients qualified for lung transplant and those who already are
recipients. Further studies regarding this issue are required as authors will explore this
issue in the future.*Address correspondence to Magdalena Latos, Department of
Cardiac, Vascular, and Endovascular Surgery and Trans-
plantology, Silesian Center for Heart Diseases in Zabrze, Medical
University of Silesia, ul. Curie-Skłodowskiej 9, 41-800, Zabrze,
Poland. E-mail: latos.magdalena93@gmail.comMODEL for End-Stage Liver Disease (MELD) score isused all over the world to assess the severity of chronic
liver disease, particularly in the process of qualification for
liver transplant [1]. Moreover, the MELD score was exam-
ined to be an outcome predictor in patients with advanced
heart failure referred for cardiac transplant evaluation [2].
There are also several studies on liver failure effects on mean
pulmonary artery pressure (mPAP) [3e5]. The aim of our
study was to assess liver function among patients qualified for
lung transplant because of end-stage lung disease, especially
among those with pulmonary arterial hypertension (PAH).0
rg/10.1016/j.transproceed.2020.03.043Toevaluate this, we used theMELD-Na score. It is calculated
using bilirubin, creatinine, sodium, and international
normalized ratio of prothrombin time levels. The minimum
score is 4 and maximum is 40. A score of 10 and above is an
indicator of higher probability of liver-related death, whereasª 2020 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1. Clinical and Demographic Features of Patients Qualified for Lung Transplant Among Those Who Died While Waiting for
Procedure and Those Who Underwent Lung Transplant
No Transplant (n ¼ 102) Transplant (n ¼ 57) P Value
Clinical and Demographic Features of
Patients at Qualification to Lung Transplant






MELD-Na score 8.11 (2.52) 8.49 (3.41) .42
FEV1, % 46.78 (17.32) 36.81 (22.48) .01
FVC, % 50.63 (19.68) 54.75 (19.78) .33
6MWT distance, mile 200.76 (146.99) 229.99 (146.11) .24
Borg's scale 4.49 (1.95) 4.6 (1.98) .76
SpO2 before 6MWT, % 89.62 (6.46) 91.18 (4.11) .11
SpO2 after 6MWT, % 75.74 (11.62) 80.98 (9.85) .006
Ht, % 44.16 (5.29) 43.58 (5.11) .51
Hg, g/dL 11.29 (2.98) 11.91 (3.28) .22
RBC, millions/dL 4.98 (1.2) 4.93 (0.56) .77
WBC, thousands/dL 9.38 (2.87) 9.18 (4.11) .73
PLT, thousands/dL 227.76 (75.55) 223.8 (73.73) .75
NT-proBNP, pg/mL 1443,72 (2825.44) 706.95 (1633.56) .11
LVEF, % 54.39 (5.48) 54.96 (8.01) .61
Clinical Features of Patients After Lung Transplant (assessed only for transplant recipients)
FEV1, % 62.17 (27.96)
FVC, % 80.53 (20.86)
Ht, % 35.3 (4.2)
Hb, g/dL 7.2 (0.94)
RBC, millions/dL 3.86 (0.55)
WBC, thousands/dL 6.62 (2.19)
PLT, thousands/dL 216.73 (58.91)
LVEF, % 53 (1.96)
Values are given as mean (SD).
6MWT, 6-minute walk test; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in first second; FVC, forced vital capacity; Hb, hemo-
globin; Ht, hematocrit; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic pulmonary fibrosis; LVEF, left ventricular ejection fraction; MELD-Na score,
Model for End-Stage Liver Disease calculated with sodium score; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PLT, platelet; RBC, right blood cell;
SpO2, oxygen saturation; WBC, white blood cell.
*Rare lung diseases not qualified elsewhere (see text).
END-STAGE LUNG DISEASE MELD SCORE 2129a score of 25 and above is a recommendation for an urgent
liver transplant. The aim of the study was to assessMELD-Na
score among patients qualified for lung transplant. An addi-
tional objective was to check whether there is a correlation
between MELD-Na and mPAP.METHODS
The study group primarily consisted of 123 patients qualified for
lung transplant in Silesian Center for Heart Diseases between
2004 and 2017. The study included only patients with right heart
catheterization. The basic clinical data and the routinely
measured laboratory parameters were collected by reviewing the
patients’ records. MELD-Na score was calculated for every pa-
tient individually using the MELD formula updated in 2016
(Table1) [6].
The study group consisted of 35.8% patients with idiopathic
pulmonary fibrosis (IPF), 26.8% patients with chronic obstructive
pulmonary disease (COPD), 20.3% patients with idiopathic pul-
monary arterial hypertension (IPAH), and 17.1% patients withother diseases, such as sarcoidosis, extrinsic allergic alveolitis, cystic
fibrosis, histiocytosis, and bronchiectasis (Table 1).
Statistical Analysis
All statistical analyses were performed in Statistica 13.3 (TIBCO
Software, Palo Alto, Calif, United States). Basic descriptive
statistics were analyzed with Shapiro-Wilk tests as well as cor-
relation analysis using Spearman r coefficient, Kaplan-Meier
survival analysis with Gehan-Wilcoxon test, and Cox regression
analysis. A P value less than .05 was deemed statistically
significant.RESULTS
The average MELD-Na score among patients qualified for
lung transplant was 8.24 (SD, 3) points, and mPAP was
35.02 (SD, 16) mm Hg. Patients with PAH obtained higher
mean MELD score (9.05 [SD, 4] points) than those without
PAH (6.45 [SD, 2] points). Mean PAP among patients with
Table 2. Correlation Between MELD-Na Score and mPAP
Analyzed Group Spearman r
Statistical
Significance
IPAH, transplant recipients 0.74 .014
IPF, transplant recipients 0.71 .047
Other,* transplant recipients 0.11 .523
Patients who died without transplant 0.34 < .001
Abbreviations: IPAH, idiopathic pulmonary arterial hypertension; IPF, idio-
pathic pulmonary fibrosis; MELD-Na, Model for End-Stage Liver Disease
calculated with sodium score; mPAP, mean pulmonary artery pressure.
*Rare lung diseases not qualified elsewhere (see text).
2130 STĄCEL, NĘCKI, LATOS ET ALPAH and without PAH was 42.3 (SD, 14) mm Hg and 18.9
(SD, 4) mm Hg, respectively.
Those patients with IPAH acquired the highest MELD
and highest mPAP results (13.1 [SD, 5] points and 57.7 [SD,
14] mm Hg, respectively).
Patients with COPD presented the lowest overall mPAP
and MELD-Na score (26.1 [SD, 12] mm Hg; 6.61 [SD, 2]
points). Patients with this underlying disease presented
highermeanMELD-Na score among those with PAH (7 [SD,
2] points; 35.93 [SD, 12] mm Hg) than those without PAH
(6.32 [SD, 1] points; 18.84 [SD, 4] mm Hg).
Patients with IPF presented higher mean mPAP and
higher MELD-Na score than those with COPD (31.67 [SD,
12] mm Hg; 7.41 [SD, 2] points). Patients with this under-
lying disease presented higher mean MELD-Na score
among those with PAH (7.74 [SD, 2] points; 36.59 [SD, 10]
mm Hg) than those without PAH (6.5 [SD, 2] points; 18
[SD, 3] mm Hg).
As stated above the main objective of the study was to
assess whether there is a correlation between MELD-Na
score and mPAP among patients qualified for lung trans-
plant. The study group was divided into 2 smaller ones
based on outcome of the qualification process. The first one
consisted of the transplant recipients. The second one
contained those who died while waiting for lung transplant.
In both groups, the distribution of key variables (MELD
and mPAP) and most of the other ones do not meet the
criteria of matching to the normal distribution; hence,
nonparametric tests were performed in this study.Table 3. Coefficients of Regression Analysis Predicti
Variables b SE t
MELD-Na score 0.09 0.12 0.56
mPAP, mm Hg 0.01 0.02 0.31
Age at qualification, y 0.01 0.02 0.27
BMI at qualification 0.08 0.07 1.27
Ht, % 0.11 0.05 5.06
Hb, g/dL 0.06 0.07 0.89
RBC, millions/dL 0.48 0.22 4.88
WBC, thousands/dL 0.00 0.06 0.00
PLT, thousands/dL 0.00 0.00 0.24
NT-proBNP, pg/mL 0.00 0.00 1.91
LVEF, % 0.02 0.03 0.48
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by
CI for relative risk; LVEF, left ventricular ejection fraction; MELD-Na, Model for End-St
pressure; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PLT, plate
95% CI for relative risk; WBC, white blood cell.Correlation analysis using Spearman r coefficient was
performed. Detailed results are presented in Table 2. It is
worth mentioning that 1. there is strong positive correlation
between MELD-Na and mPAP among patients who un-
derwent lung transplant because of IPF, 2. similar yet not as
strong correlation was noticed among lung transplant can-
didates who died on the waiting list, and 3. strong negative
correlation between aforementioned parameters was
observed in the group of lung recipients who received
transplants because of IPAH.
As the following correlations were observed, it was
decided to perform survival analysis by using Cox regression
to estimate what factors could be the predictors of death in
2 groups. The first one consisted of those who died while
waiting for lung transplant. The second one contained the
transplant recipients. The statistical model developed for
the aforementioned analysis contained several factors. Re-
sults for the first and second group are presented in Table 3
and Table 4, respectively.
The model constructed for patients awaiting transplant
showed a weak correlation with the risk of death during
observation, as evidenced by the value of R2 ¼ 0.17. He-
matocrit and red blood counts were significantly associated
with the risk of death. An increase in hematocrit of 1 per-
centage point resulted in a decrease in the risk of death of
1.117  (1.014-1.230). In turn, an increase in the number of
erythrocytes by 1 million/dL increased the risk of death by
1.612  (1.055-2.462). The other predictors included in the
analysis were not significantly associated with the risk of
death of patients awaiting transplant. Detailed results are
presented in Table 3.
For patients after transplant the analysis showed a very
strong correlation with the risk of death during observation,
as evidenced by the value of R2 ¼ 0.87. Several factors
were included in the analysis. The MELD score, mPAP,
N-terminal prohormone of brain natriuretic peptide level,
and red blood cell count were the only independent variables
significantly associated with the risk of death.
An increase in MELD score of 1 point increased the risk
of death by 1.778  (1.082-2.922). An increase in mPAP byng Survival of Patients Awaiting Lung Transplant
P Value RR LL UL
.454 0.916 0.727 1.153
.580 0.990 0.955 1.026
.605 0.988 0.942 1.036
.259 1.084 0.942 1.247
.025 0.895 0.813 0.986
.344 1.066 0.934 1.215
.027 1.612 1.055 2.463
.967 0.997 0.880 1.130
.627 1.001 0.996 1.006
.167 1.000 1.000 1.000
.488 1.021 0.963 1.083
height in meters squared); Hb, hemoglobin; Ht, hematocrit; LL, lower limit of 95%
age Liver Disease calculated with sodium score; mPAP, mean pulmonary arterial
let; RBC, red blood cell; RR, relative risk; SE, standard error; UL, upper limit of
Table 4. Coefficients of Regression Analysis Predicting Survival of Patients After Transplant
Variables b SE t P Value RR LL UL
MELD- Na score 0.58 0.25 5.15 .023 1.778 1.082 2.922
mPAP, mm Hg 0.26 0.12 4.58 .032 0.772 0.609 0.979
Age at qualification, y 0.09 0.05 2.52 .113 1.090 0.980 1.213
BMI at qualification 0.08 0.16 0.24 .625 1.079 0.796 1.463
Ht, % 0.23 0.18 1.51 .218 0.798 0.557 1.143
Hb, g/dL 0.07 0.20 0.13 .715 1.077 0.723 1.604
RBC, millions/dL 3.28 1.62 4.12 .042 26.709 1.118 637.946
WBC, thousands/dL 0.25 0.19 1.79 .181 0.778 0.539 1.124
PLT, thousands/dL 0.00 0.01 0.26 .609 1.003 0.992 1.014
NT-proBNP, pg/mL 0.00 0.00 4.50 .034 1.000 1.000 1.001
LVEF, % 0.06 0.09 0.42 .517 1.057 0.894 1.249
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); Hb, hemoglobin; Ht, hematocrit; LL, lower limit of 95%
CI for relative risk; LVEF, left ventricular ejection fraction; MELD-Na, Model for End-Stage Liver Disease calculated with sodium score; mPAP, mean pulmonary arterial
pressure; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PLT, platelet; RBC, red blood cell; RR, relative risk; SE, standard error; UL, upper limit of
95% CI for relative risk; WBC, white blood cell.
END-STAGE LUNG DISEASE MELD SCORE 21311 mm Hg resulted in a decrease in the risk of death of
1.296  (1.022-1.642). An increase in N-terminal pro-
hormone of brain natriuretic peptide level of 1 pg/mL
increased the risk of death by 1.00044  (1.00033-1.00080),
and increase in the number of erythrocytes by 1 million/dL
increased the risk of death by 26.709  (1.118-637.95). The
other predictors included in the analysis were not signifi-
cantly associated with the risk of death among lung trans-
plant recipients. Data are presented in Table 4.
In addition, a series of Kaplan-Meier survival estimations
were performed to advance the study of relationship be-
tween the MELD score, mPAP, and survival of patients
awaiting transplant and after transplant in every diagnosis.
The analyses compared patients with low (< 7) and high (>
7) MELD results as well as patients with normal (< 20 mm
Hg) and elevated (> 20 mm Hg) mPAP. Cutoff point of
MELD and mPAP were assessed by median. Analyses were
performed by primary disease (IPAH, IPF, or other). These
groups were compared by the Gehan-Wilcoxon test.
It turned out that a statistically significant difference ap-
plies only to transplant recipients with a diagnosis other
than IPAH and IPF. In this group, significantly better sur-
vival was observed in patients with elevated mPAP.DISCUSSION
Patients may become lung transplant recipients because of
primary pulmonary hypertension or other lung diseases with
concomitant secondary pulmonary hypertension. As none
of them were qualified with severe cirrhotic liver failure,
classic MELD results were expected to be low. Authors of
this article decided to use MELD-Na as some studies sug-
gest that hyponatremia is considered to be a predictor of
death not only among liver transplant candidates with
cirrhosis but also among those with ascites [7,8]. This clin-
ical symptom is frequently presented by patients qualified
for lung transplant because of primary pulmonary hyper-
tension. The same studies also assessed that MELD-Na is a
better predictor of death among patients with initially low
MELD [7,8]. Assessment of these MELD-based parametersis useful not only among liver transplantologists. The study
by Puentes et al proved its value as a tool of assessment
among patients with advanced liver cirrhosis requiring
palliative care [9]. The study by Godfrey et al demonstrated
that MELD-Na score is the short-term mortality predictor
among patients with severe liver disease who are in need of
emergency surgery [10]. The higher the MELD-Na score,
the worse the survival. This parameter is even useful among
surgical patients without cirrhosis as study by Coakley et al
describes MELD-Na to be an independent predictor of
anastomotic leak in partial rectal resections [11]. Applica-
tion of MELD or its derivatives was also tested among
diseases beyond abdominal cavity. There are studies
assessing the usefulness of MELD score and its derivatives
among patients qualified for heart transplant. Ortiz-
Bautista et al used MELD-XI (MELD’s derivative
excluding the international normalized ratio of prothrom-
bin time) as a predictor of mortality after adult heart
transplant [12]. Their work evaluated this derivative to be
scarce as it considers its discrimination ability to be poor.
Such finding was contradicted by Deo et al as their study
states that hepatorenal dysfunction measured by means of
MELD-XI is in fact the predictor of mortality and
morbidity among heart transplant recipients [13]. Other
studies have combined MELD-XI with other predictors.
Szczurek et al conducted the study assessing the prognostic
value of Heart Failure Survival Score combined with
MELD-XI and Heart Failure Survival Score combined with
modified MELD [14]. Their study claims that these 2 pa-
rameters may effectively guide the selection of patients for
heart transplant and predict 1-year survival among patients
with advanced heart failure.
After researching and reviewing all the accessible liter-
ature, authors of this study did not find any article
assessing the MELD score or/and its derivatives among
patients qualified for lung transplant or/and pulmonary
graft recipients. This might be the first article pertaining to
this topic. However, there are articles describing MELD as
one of the risk factors of respiratory failure in the early
postoperative period after liver transplant [15]. The study
2132 STĄCEL, NĘCKI, LATOS ET ALpublished by Aydin et al also points out that high MELD
score also can be a significant risk factors for mortality
among liver transplant recipients with postoperative pul-
monary complications [16]. Our study assessed that
MELD-Na and mPAP are not predictors of survival
among patients awaiting lung transplant because of end-
stage primary pulmonary hypertension, COPD, or IPF
(Table 3). However, results obtained at qualification can
predict the survival of patients after lung transplant. What
is more, there is a strong correlation with the risk of death
during observation after lung transplant. Our study
assessed that risk of death increases with MELD-Na score
and mPAP among lung transplant recipients. This finding
is consistent among patients with IPF and lung diseases
other than IPAH (Table 4). The most surprising finding
was that there is a strong negative correlation between
MELD-Na and mPAP among patients with the highest
values of pulmonary pressure among entire study group
(Table 2). As this study is the first pertaining to this issue,
the reason for such a result is unclear. The authors are
aware of the facts that serum sodium levels (component of
MELD-Na equation) may be vulnerable to alterations by
diuretic use and intravenous fluid administrations. It is
consistent with the treatment of severe forms of IPAH as
diuretics in extremely large doses are used as a treatment
concomitant to prostanoids, endothelin receptor antago-
nists, and phosphodiesterase 5 inhibitors. Nevertheless,
other factors must be taken into consideration regarding
this particular issue.
CONCLUSIONS
This is the first study in the worldwide literature assessing
MELD-Na as a predictor of survival among patients quali-
fied for lung transplant and those who already are re-
cipients. MELD-Na and mPAP are the outcome predictors
after lung transplant regardless of underlying disease. There
is a strong positive correlation between mPAP and MELD-
Na among lung transplant recipients who receive transplant
because of IPF, but in IPAH lung transplant recipients there
is a strong negative correlation between mPAP and MELD-
Na. Further studies regarding this issue are required as
authors will explore this issue in the future.
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